RxDoctor Payments Data

Andrew Grollman, MD

Urology · Albuquerque, NMNPI 1811157100

Payments from drug & device makers

What this record shows

The money is spread across several categories — education (50.3%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Intuitive Surgical at 52.0% of the total. Reporting peaked in 2020 at $8,757 and has fallen 91.3% since, to $764 in 2025. Among urology clinicians in NM with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$16,217in general payments, 2019–2025

Across 122 payments — averaging $132.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$8K
  • Neotract Inc.$3K
  • Olympus America Inc.$1K
  • Medtronic$1K
  • Astellas Pharma US Inc$487
  • Teleflex LLC$467
  • plus $1K from 18 others

What the payments were for

  • Travel & lodging$2,53516%
  • Food & beverage$5,52734%
  • Education$8,15550%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,217 in reported general payments places this provider in the 90th percentile of 46 urology providers in New Mexico.

See all urology providers in New Mexico

Medicare billing

Part B allowed, 2024
$253,672
Medicare patients
576
Services billed
3,531

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron51$45,207
Tamsulosin Hcl384$6,907
Solifenacin Succinate49$3,825
Finasteride220$3,374
Oxybutynin Chloride ErOxybutynin Chloride252$2,994
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst185$2,642
Ketorolac Tromethamine61$1,040
Ciprofloxacin Hcl148$517
Cephalexin29$190
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen23$115
Clindamycin Hcl14$82
Tramadol Hcl41$56

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$487$45,20751 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 46 urology providers in New Mexico.

Other urology in Albuquerque

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →